With box warnings

Without box warnings

Branded

Generic

4 results

inrebic
(Fedratinib Hydrochloride)
Celgene Corporation
Usage: INREBIC® is indicated for treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF), including cases post-polycythemia vera or post-essential thrombocythemia.
jakafi
(ruxolitinib)
Incyte Corporation
Usage: Jakafi is indicated for treating intermediate or high-risk myelofibrosis, polycythemia vera in adults intolerant to hydroxyurea, and steroid-refractory acute and chronic graft-versus-host disease in patients aged 12 and older who have not responded to prior systemic therapies.
ojjaara
(Momelotinib)
GlaxoSmithKline LLC
Usage: OJJAARA is indicated for treating intermediate or high-risk myelofibrosis (MF), including primary and secondary MF (post-polycythemia vera and post-essential thrombocythemia), in adults with anemia.
vonjo
(Pacritinib)
CTI BioPharma Corp.
Usage: VONJO is indicated for treating adults with intermediate or high-risk primary or secondary myelofibrosis (MF) and a platelet count below 50 × 10⁹/L. This approval is based on accelerated approval due to spleen volume reduction, pending confirmation of clinical benefit in further trials.

Medications for Myelofibrosis

inrebic